OPKO Health Inc. — Director's Dealing 2014

Mar 18, 2014

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden hours per response. . . . 0.5
1. Name and Address of Reporting Person*
OPKO Health, Inc.
03/17/2014
---
(Last) (First) (Middle)
4400 Biscayne Blvd.
Biozone Pharmaceuticals, Inc. (BZNE)
(Street)
Miami FL 33137
(City) (State) (Zip)
☐ Director ☐ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)
☐ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person
Table I — Non-Derivative Securities Beneficially Owned
1. Title of Security
(Instr.4)
(Instr. 4)
(Instr. 5)
(Instr. 5)
Common Stock

---

FORM 3 (continued)

Table II — Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Exercisable Date	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(1)	(1)	Common Stock	34893242	(1)	D
Common Stock Warrants	1/17/2014	1/17/2024	Common Stock	1000000	$0.50	D

Explanation of Responses: See attached footnotes page.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• If the form is filed by more than one reporting person, see Instruction 5(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Adam Logal, Vice President-Finance, Chief Accounting Officer, and Treasurer 3/17/2014 Date

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

---

FORM 3 (continued)

Explanation of Responses

(1) Represents approximately 170,142 shares of Series B preferred stock. The Series B shares automatically convert into 205.08308640 shares of Common Stock when the issuer increases its authorized capital to enable all of the outstanding Series B holders to convert. The Series B shares were issued on January 2, 2014 and do not expire.